Profiles of Innate Immune Cell Infiltration and Related Core Genes in Psoriasis

Xiaoting Gong
Tongde Hospital Of Zhejiang Province  https://orcid.org/0000-0001-7032-8771

Wei Wang ( wangweihz8@163.com )
Tongde Hospital Of Zhejiang Province  https://orcid.org/0000-0002-8511-1775

Research article

Keywords: Psoriasis, Innate immunity, CIBERSORT, Disease severity, Treatment response

DOI: https://doi.org/10.21203/rs.3.rs-63594/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

**Background:** Psoriasis is an inflammatory skin disease with substantial morbidity. Numerous patients with psoriasis experience recurrence after therapy. The underlying mechanism about psoriasis is still not fully understood. Some evidences suggest that innate immunity may play an unexpected and important role in active severe psoriasis. In this work, the deconvolution algorithm CIBERSORT was conducted to identify the infiltration of innate immune cells and related core genes in psoriatic plaque.

**Results:** Datasets from the Gene Expression Omnibus, including 407 psoriasis lesional, 373 non-lesional and 91 normal skin samples, were downloaded for analysis. Considerable differences of the innate immune cell composition were uncovered between psoriatic plaque and control skin. Results revealed that γδ T cells, resting NK cells, M0 macrophages, M1 macrophages, activated dendritic cells and neutrophils were significantly increased in psoriatic skin, while resting mast cells and active NK cells were significantly decreased. Moreover, the proportion of M0 macrophages or resting mast cells was found to be associated with disease severity. Spearman correlation analysis suggests that RORC and S100A12 genes were related to disease severity, while genes including S100A12, CLEC4C, IL-19, AIM2, IL-17F, PPARGC1A, were correlated with biologics treatment response.

**Conclusions:** Collectively, this work displays innate immune status in psoriatic skin, and provides novel clues for clinical decisions and mechanism study.

**Background**

Psoriasis is a chronic inflammatory skin disorder, which is related with multiple comorbidities and affects 125 million people worldwide[1]. It substantially diminishes life quality of patients and is incurable. It could be recurrent under stimulation with risk factors, such as skin trauma, infection, stress, certain medications including interferon, β blocker, and lithium[2]. Psoriasis is thought to be triggered by innate and adaptive immune components, interacting with skin tissue cells[3]. Numerous studies point that interleukin (IL)-23/IL-17 axis plays a central role in psoriasis pathogenesis[3]. It has been validated by the therapeutic efficacy of blocking IL-23 and IL-17 pathway in moderate-to-severe psoriasis, such as ustekinumab and brodalumab[4]. However, these clinical methods have limitations, and symptoms are likely to reappear upon cessation of therapy.

Accumulating circumstantial evidences suggest that adaptive immune response is more likely to play a critical role in mild stable psoriasis, in contrast, innate immunity seems to be predominate in active severe disease state[5]. Innate immune cells are able to respond rapidly to skin injury and infection, and secrete large amounts of inflammatory mediators. Besides Th17 cells, multiple innate immune cells could produce IL-17, including γδ T cells, natural killer (NK) cells, invariant natural killer (iNKT) cells, mast cells, macrophages, neutrophils and IL-17 innate lymphoid cells. These innate-derived IL-17 act as critical element in immune response to self antigens and sustaining inflammation, involving in psoriasis pathogenesis[6]. Moreover, upon activation, innate immune system could undergo epigenetic and
metabolic reprogramming, leading to enhanced responsiveness to a second challenge\cite{7}. This process is called ‘trained immunity’, in the nature of innate immune memory, which could contribute to detrimental outcomes in chronic inflammatory diseases\cite{7}. Therefore, further investigation of innate immune status in psoriatic plaque is important to understand the pathogenesis of psoriasis and improve the therapeutic efficacy.

In this work, we applied the CIBERSORT algorithm with microarray data downloaded from the Gene Expression Omnibus (GEO) database, to calculate innate immune cell proportion in psoriatic skin. A list of related core genes were screened by correlation analysis with clinical characteristics. The combination study of innate immune cells and related genes supplies a better understanding of the innate immune response in psoriasis and provides clues for clinical application.

**Results**

**Composition of innate immune cells in psoriatic lesion**

The fraction of infiltrated innate immune cells was evaluated in psoriasis lesional, non-lesional and normal skin. Among the total samples, 316 lesional, 219 non-lesional and 64 normal samples were eligible for CIBERSORT \( p < 0.05 \). The expression signature of 11 innate immune cell types was analyzed. Activated mast cells and eosinophils were excluded, as they were not significantly found in these samples after calculation. As shown in Figure. 1, \( \gamma\delta \) T cells, resting NK cells, M0 macrophages, M1 macrophages, activated dendritic cells and neutrophils were upregulated in psoriasis lesional skin, compared with non-lesional or normal skin. Activated NK cells and resting mast cells were downregulated.

**Association between innate immune cells and clinical manifestation in psoriasis patients**

In this study, the severity of psoriasis was indicated by Psoriasis Area and Severity Index (PASI). Based on PASI, the severity was classified into three levels: mild (0–12), moderate (12–18) and severe (>18) (Table. 1). Among these innate immune cells, proportion of M0 macrophages and resting mast cells showed correlation with disease severity (Figure. 2). The fraction of M0 macrophages was lower in moderate or severe psoriasis, compared with mild psoriasis. The proportion of resting mast cells in severe was also lower than in mild psoriasis. The therapeutic efficacy was represented by drug's PASI efficacy profile, which is the percentage of reduction in the PASI score after 12 weeks treatment (Table. 1). There was no correlation between innate immune cell fraction and therapeutic efficacy of brodalumab or ustekinumab (data not shown).

**Identification Of Differentially Expressed Innate Immune Genes**
Limma package\cite{33} was utilized to screen the differentially expressed genes (DEGs) between psoriasis lesional and control (non-lesional or normal) skin. The filter criteria of DEGs was set as: adjusted \( p \)-value < 0.05, and \( \log_2| \text{fold change (FC)} | > 1 \). The list of genes involved in the innate immune modulation was downloaded from www.innatedb.com database\cite{34}. The innate immune genes among the DEGs were identified by venn diagram.

### Discovery Of Core Genes Associated With Clinical Parameters

Figure. 4A shows that 7 differentially expressed innate immune genes were significantly correlated with clinical indicators (Table. 1). These genes were identified as core genes. Among these genes, RORC and S100A12 were related to disease severity. S100A12, CLEC4C and AIM2 were positively correlated with the therapeutic efficacy of brodalumab, while IL-19 was negatively correlated. AIM2, IL-17F and PPARGC1A were negatively associated with ustekinumab treatment response.

### Comprehensive correlation analysis of core genes and innate immune cells

As shown in Figure. 4B, core genes showed close connection with fraction of innate immune cells. Genes such as S100A12, IL-19, AIM2, IL-17F were positively correlated with activated dendritic cells and negatively correlated with resting mast cells, while RORC and PPARGC1A were complete opposite. IL-19 and IL-17F were positively related to M0 macrophages, meanwhile IL-19 and AIM2 were positively associated with M1 macrophages.

### Predicted Function Of Core Genes In Psoriasis

To explore the potential function of core genes in psoriasis, GSEA was performed for KEGG analysis (Fig. 5). All or part of pathways involving RIG-I-like receptor signaling, NOD-like receptor signaling, toll-like receptor signaling, cytosolic DNA-sensing pathway were significantly enriched and positively correlated with S100A12, CLEC4C, IL-19, IL-17F and AIM2, whereas negatively correlated with PPARGC1A. The pathways associated with ubiquitination-proteasome system were significantly regulated by RORC and S100A12 alteration in psoriasis.

### Discussion

Psoriasis is an immune-mediated skin disease. Although great advances have been made in search for psoriasis pathogenesis and treatment, therapeutic approaches are still limited for the cure. In this work, we took advantage of big data analysis, in combination with CIBERSORT algorithms, to explore novel insights into the innate immune status in psoriasis and identify prognostic biomarkers.
We found considerable differences of innate immune cell composition between psoriatic skin and control group (non-lesional or normal skin). Results revealed that γδ T cells, resting NK cells, M0 macrophages, M1 macrophages, activated dendritic cells and neutrophils were significantly increased in psoriatic skin, while resting mast cells and active NK cells were significantly decreased. Moreover, the proportion of M0 macrophages was associated with disease severity and treatment efficacy. Macrophages are considered to originate from peripheral monocytes, which enter tissue and differentiate under stimulation of the local environment. Unactivated M0 macrophages could polarize into M1 or M2 macrophages under different cytokines. M1 macrophages are implicated in activating inflammatory response, while M2 macrophages are involved in resolution of inflammation[8]. Previous study showed that when peripheral monocytes derived from psoriasis patients were induced in vitro, the ratio of M1/M2 macrophage polarization was higher, compared with healthy control[9]. It indicates that monocytes in psoriasis might undergo a reprogramming process-trained immunity[7], acquiring the preference to M1 polarization. Derived from monocytes, M0 macrophages in psoriatic plaque might also be reprogrammed in the same way. In addition, IL-23 promoted expression of IL-17A, IL-17F, IFN-γ and IL-22 in M0 macrophages, and IL-23-treated M0 macrophages significantly enhanced psoriasis-like dermatitis in mice model[10]. Moreover, M0 macrophages were susceptible to this IL-23-driven M(IL-23) differentiation, while surprisingly M1 and M2 macrophages were highly resistant to polarization into M(IL-23) macrophages[10]. We unexpectedly found that IL-17F expression was positively related to the proportion of M0 macrophages in lesional skin. IL-23 is highly expressed in psoriatic skin. Under IL-23 stimulation, M0 macrophages might play an unexpected and important effect in psoriasis pathogenesis.

γδ T cells were source of IL-17 and increased in psoriatic skin[11]. Murine models lacking γδ T revealed inhibited psoriasiform symptoms and inflammation[11][12]. In psoriasis vulgaris patient blood, NK cells were reported to have reduced cytotoxicity and production of pro-inflammatory cytokines TNF-α and IFN-γ[13]. However, another study showed that NK cells isolated from psoriatic skin secreted more IFN-γ[14]. Researches about NK cells involved in psoriasis are insufficient, and the role in pathogenesis is not clear. Activated DCs played a pivotal role in psoriasis pathogenesis. They not only initiated the inflammation, but also sustained it[15]. Activated mast cells were elevated in psoriatic plaque and produced IL-17, IL-22[16]. In our analysis, the fraction of activated mast cells was rare. It is possible that CIBERSORT enumerates mainly IgE-activated mast cells, for which gene expression signature employed for deconvolution was acquired from mast cells induced by IgE[17]. While activation of mast cells by IL-1 was an important process in skin inflammation and implicated in psoriasis pathogenesis[18]. Recent studies revealed that neutrophils in psoriatic plaque generated abundant neutrophil extracellular trap, degranulation and the respiratory burst with ROS production, contributing to the pathogenesis of psoriasis[19]. Collectively, different innate immune cells infiltrated in skin could play various roles in psoriasis development and progression. The specific function of some types remain to be elucidated.

Further analysis found that RORC and S100A12 were associated with psoriasis severity. The nuclear receptor retinoic acid receptor-related orphan receptor gamma (murine form “RORγ” or human form
“RORC”) was a key transcription factor for the production of IL-17 and involved in inflammatory response of psoriasis\cite{20}. Compared with severe psoriasis, mild psoriasis was characterized by higher IL-17A expression in psoriatic lesion\cite{21}, which is consistent with the alteration of RORC in our study. Among S100 proteins, serum S100A12 level revealed the closest association with psoriasis disease activity-PASI\cite{22}. We also found this positive correlation in psoriatic plaque. Ubiquitination, a type of post-translational modification, is viewed as an important regulator in psoriasis pathogenesis, through modulation of key transcription factors or signaling molecules\cite{22}. RORγt, a splice variant of RORγ, could be modulated by both ubiquitination and deubiquitylation\cite{23}. In this work, GSEA analysis indicated that low RORC expression or high S100A12 expression was associated with ubiquitination-proteasome system. This suggests that expression of RORC and S100A12 might be regulated by ubiquitination, which is related with the modulation of psoriasis severity.

Ustekinumab and brodalumab are monoclonal antibodies applied for psoriasis treatment. Ustekinumab can inhibit IL-23 pathway by binding to the common p40 subunit of IL-12/IL-23, while brodalumab targets IL-17 receptor A and blocks IL-17 pathway. This study revealed that multiple genes were related with therapeutic efficacy. After activation, AIM2 assembles inflammasome, driving IL-1β secretion and contributing to psoriasis\cite{24}. Ngoungoure\cite{25} reported that M1 polarized macrophages expressed higher AIM2, compared with resting THP-1 macrophages. In this work, AIM2 expression was positively correlated with M1 macrophage fraction in psoriatic plaque, indicating that AIM2 might regulate psoriasis progression through modulating M1 macrophages. However, its relationship with treatment response was inconsistent in brodalumab and ustekinumab. AIM2 might play a different effect on IL-17 and IL-23 pathway and it needs to be further explored.

CLEC4C is a plasmacytoid dendritic cells (pDCs)-specific receptor. Cross-linking CLEC4C with monoclonal antibodies could lead to receptor internalization, rapid Ca\textsuperscript{2+} influx, and inhibition of IFN-I response in pDCs\cite{26}. We found CLEC4C expression was positively correlated with therapeutic efficacy with brodalumab, which might be a result of CLEC4C engagement induced by monoclonal antibody brodalumab. CLEC4C could not only predict brodalumab treatment response, but also be exploit as a target for selecting therapeutic monoclonal antibodies. IL-19 could amplify IL-17A effects on keratinocytes in psoriasis\cite{27}. We found IL-19 expression was negative correlated with anti-IL-17RA therapy.

IL-17F is a subtype of IL-17. Previous study reported that IL-17F polymorphism rs763780 was associated with better efficacy of anti-TNF therapy\cite{28}. In this study, low IL-17F expression was also linked to better response to anti-IL-23 treatment. PPARGC1A interacts with PPARγ and is a transcriptional coactivator. During acute colitis, PPARGC1A activation in intestinal CD11b\textsuperscript{-}CD103\textsuperscript{+}DCs promoted production of retinoic acid, which subsequently acted on CD11b\textsuperscript{+}CD103\textsuperscript{+}DCs to suppress IL-23 secretion\cite{29}. There is no report about PPARGC1A in psoriasis. Based on previous work and our finding of negative correlation between PPARGC1A and activated DCs, we presume that PPARGC1A might inhibit DC production of IL-23. Therapy by blocking IL-23 might not act well in moderate-to-severe psoriasis with high PPARGC1A
expression, for suppressed IL-23 may not be therapy target in these patients. In sum, these results indicate that these genes may have important clinical implications in psoriasis and deserve deeper investigation.

However, this study has limitation. The number of samples for clinical association analysis was relatively small. Large sample clinical studies need to be conducted to validate our results.

**Conclusions**

Our study provides new clues about innate immune statues in psoriatic skin. Eight types of innate immune cells showed obvious association with psoriasis, and M0 macrophage or resting mast cell proportion revealed significant difference when comparing disease severity. Seven core genes related to clinical parameters were analyzed and may play crucial roles in disease progression. Further study of these genes in psoriasis could identify targets for therapy and biomarkers for individualizing treatment strategies.

**Methods**

**Microarray data acquisition and preprocessing**

Gene expression datasets and sample information were acquired from the GEO database ([www.ncbi.nlm.nih.gov/geo](http://www.ncbi.nlm.nih.gov/geo)). Eleven datasets (Affymetrix GPL570 Platform, Affymetrix Human Genome U133 Plus 2.0 Array) were downloaded, including GSE14905, GSE13355, GSE67853, GSE69967, GSE30999, GSE117468, GSE53552, GSE50790, GSE47751, GSE41663 and GSE78097. In total, 407 psoriasis lesional, 373 non-lesional and 91 normal skin samples were selected for further analysis. Data preprocessing included background correction and quantile normalization by Affy package[^30] in R (v3.6.3). Then, probes were converted into gene symbols. After batch normalization by sva package[^31], the merged data was processed to remove null values by KNN method in impute package[^32].

**Immune Infiltration Analysis**

CIBERSORT[^17] is an analytical tool to estimate the proportion of diversified cell types from complex tissues based on gene expression data. The gene signature file LM22 was used to identify immune cells infiltrated in skin. Samples with CIBERSORT p-value < 0.05 were selected for further analysis.

**Gsea-based Kegg Pathway Analysis**

Gene set enrichment analysis (GSEA) is an analytical method to identify if predefined gene sets are functional enriched, by comparing genes from different groups. According to the median value of the core gene, samples were divided into high-expression group and low-expression group. Kyoto Encyclopedia of
Genes and Genomes (KEGG) pathway enrichment analysis was carried out by GSAE. The nominal $p$-value < 0.05 and False discovery rate < 25% were set as the cut-off criteria.

**Statistical analysis**

All statistical analyses were conducted in R v3.6.3 software. The proportion of innate immune cells between different groups were compared by Wilcoxon rank-sum test. Spearman correlation analysis was performed to reveal the relationship between expression of genes and parameters, such as disease severity, treatment response and innate immune cells. $P$-value < 0.05 was considered statistically significant.

**Abbreviations**

AIM2: Absent in melanoma 2; CLEC4C: C-type lectin domain family 4 member C; DEGs: Differentially expressed genes; GEO: Gene Expression Omnibus; GSEA: Gene set enrichment analysis; IFN: Interferon gamma; IL-17: Interleukin-17; IL-23: Interleukin-23; iNKT: invariant natural killer; KEGG: Kyoto Encyclopedia of Genes and Genomes; NK: Natural killer; PASI: Psoriasis disease activity; PPARGC1A: PPARG coactivator 1 alpha; RORC: RAR related orphan receptor C; ROS: Reactive oxygen species; S100A12: S100 calcium binding protein A12; TNF: Tumor necrosis factor.

**Declarations**

**Ethics approval and consent to participate**

Not applicable.

**Consent for publication**

Not applicable.

**Availability of data and materials**

The datasets analyzed in this study are openly available in GEO database at http://www.ncbi.nlm.nih.gov/geo.

**Competing interests**

The authors declare that they have no competing interests.

**Funding**

This study was supported by grants from the National Natural Science Foundation of China (no. 81774026). The funders did not participate in the design of the study and collection, analysis, and
interpretation of data, and in writing the manuscript.

**Authors' contributions**

XG and WW designed the experiments; XG analyzed the data; XG and WW wrote the manuscript. All authors read and approved the final manuscript.

**Acknowledgements**

Not applicable.

**References**

1. Michalek IM, Loring B, John SM. A systematic review of worldwide epidemiology of psoriasis. J Eur Acad Dermatol Venereol. 2017;31(2):205–12.
2. Conrad C, Gilliet M. Psoriasis: from Pathogenesis to Targeted Therapies. Clinical Reviews in Allergy Immunology. 2018;54(1):102–13.
3. Schn MP. Adaptive and Innate Immunity in Psoriasis and Other Inflammatory Disorders. Front Immunol. 2019;10:1764.
4. Armstrong AW, Read C, Pathophysiology. Clinical Presentation, and Treatment of Psoriasis. A Review JAMA. 2020;323(19):1945–60.
5. Christophers E, Kerkhof PCM. Severity, heterogeneity and systemic inflammation in psoriasis. J Eur Acad Dermatol Venereol. 2019;33(4):643–7.
6. Natasa I, Kenji D, Alberto M, Carlo S. Interleukin-17 and innate immunity in infections and chronic inflammation. J Autoimmun. 2015;60:1–11.
7. Netea MG, Domínguez-Andrés J, Barreiro LB, Chavakis T, Divangahi M, Fuchs E, et al. Defining trained immunity and its role in health and disease. Nat Rev Immunol. 2020;20(6):375–88.
8. Uttarkar S, Brembilla NC, Boehncke WH. Regulatory cells in the skin: Pathophysiologic role and potential targets for anti-inflammatory therapies. J Allergy Clin Immunol. 2019;143(4):1302–10.
9. Shang-Hung L, Hung-Yi C, Ji-Chen H, Chih-Hung L, Chang-Chun H. Treatment with TNF-α inhibitor rectifies M1 macrophage polarization from blood CD14 + monocytes in patients with psoriasis independent of STAT1 and IRF-1 activation. J Dermatol Sci. 2018;91(3):276–84.
10. Yuzhu H, Linnan Z, Hongling T, Hai-Xi S, Ruoyu W, Lianfeng Z, Yong Z. IL-23-induced macrophage polarization and its pathological roles in mice with imiquimod-induced psoriasis. Protein Cell. 2018;9(12):1027–38.
11. Cai Y, Shen X, Ding C, Qi C, Li K, Li X, et al. Pivotal role of dermal IL-17-producing gammadelta T cells in skin inflammation. Immunity. 2011;35:596–610.
12. Pantelyushin S, Haak S, Ingold B, Kulig P, Heppner FL, Navarini AA, et al. Rorγ+ innate lymphocytes and γδ T cells initiate psoriasiform plaque formation in mice. J Clin Invest. 2012;122(6):2252–6.
13. Dunphy SE, Sweeney CM, Kelly G, Tobin AM, Kirby B, Gardiner CM. Natural killer cells from psoriasis vulgaris patients have reduced levels of cytotoxicity associated degranulation and cytokine production. Clin Immunol. 2017;177:43–9.

14. Ottaviani C, Nasorri F, Bedini C, de Pità O, Girolomoni G, Cavani A. CD56brightCD16(-) NK cells accumulate in psoriatic skin in response to CXCL10 and CCL5 and exacerbate skin inflammation. Eur J Immunol. 2006;36(1):118–28.

15. Wang A, Bai YP. Dendritic cells: The driver of psoriasis. The Journal of Dermatology. 2020;47(2):104–13.

16. Mashiko S, Bouguermouh S, Rubio M, Baba N, Bissonnette R, Sarfati M. Human mast cells are major IL-22 producers in patients with psoriasis and atopic dermatitis. J Allergy Clin Immunol. 2015;136(2):351–9.

17. Newman AM, Liu CL, Green MR, Gentles AJ, Feng W, Xu Y, et al. Robust enumeration of cell subsets from tissue expression profiles. Nat Methods. 2015;12(5):453–7.

18. Caraffa A, Conti C, Ovidio CD, Gallenga CE, Tettamanti L, Mastrangelo F, et al. New concepts in neuroinflammation: Mast cells pro-inflammatory and anti-inflammatory cytokine mediators. J Biol Regul Homeost Agents. 2018;32(3):449–54.

19. Chiang CC, Cheng WJ, Korinek M, Lin CY, Hwang TL. Neutrophils in Psoriasis. Front Immunol. 2019;10:2376.

20. Capone A, Volpe E. Transcriptional Regulators of T Helper 17 Cell Differentiation in Health and Autoimmune Diseases. Front Immunol. 2020;11:348.

21. Kim J, Bissonnette R, Lee J, Rosa JC, Suárez-Fariñas M, Lowes MA, Krueger JG. The Spectrum of Mild to Severe Psoriasis Vulgaris Is Defined by a Common Activation of IL-17 Pathway Genes, but with Key Differences in Immune Regulatory Genes. Journal of Investigative Dermatology. 2016;136(11):2173–82.

22. Wilsmann-Theis D, Wagenpfeil J, Holzinger D, Roth J, Koch S, Schnautzet S, et al. Among the S100 proteins, S100A12 is the most significant marker for psoriasis disease activity. J Eur Acad Dermatol Venereol. 2016;30(7):1165–70.

23. Luting Y, Weinan G, Shaolong Z, Gang W. Ubiquitination-proteasome system: A new player in the pathogenesis of psoriasis and clinical implications. J Dermatol Sci. 2018;89(3):219–25.

24. Tang L, Zhou F. Inflammasomes in Common Immune-Related Skin Diseases. Front Immunol. 2020;11:882.

25. Ngoungoure FP, Owona BA. Withaferin A modulates AIM2 inflammasome and caspase-1 expression in THP-1 polarized macrophages. Exp Cell Res. 2019;383(2):111564.

26. Pellerin A, Otero K, Czerkowicz JM, Kerns HM, Shapiro RI, Ranger AM, et al. Anti-BDCA2 monoclonal antibody inhibits plasmacytoid dendritic cell activation through Fc-dependent and Fc-independent mechanisms. Embo Molecular Medicine. 2015;7(4):464–76.

27. Witte E, Kokolakis G, Witte K, Philipp S, Doecke W, Babel N, et al. IL-19 Is a Component of the Pathogenetic IL-23/IL-17 Cascade in Psoriasis. Journal of Investigative Dermatology.
28. Prieto-Perez R, Solano-Lopez G, Cabaleiro T, Roman M, Ochoa D, Talegon M, et al. The polymorphism rs763780 in the IL-17F gene is associated with response to biological drugs in patients with psoriasis. Pharmacogenomics. 2015;16(15):1723–31.

29. Jing J, In-Hyuk J, Shin HM, Sejin J, Se-Jin J, Seong-Keun S, et al. CD137 Signaling Regulates Acute Colitis via RALDH2-Expressing CD11b⁺CD103⁺ DCs. Cell Reports. 2020;30(12):4124–36.

30. Irizarry A, Bolstad M, Collin F, Cope M, Hobbs B, Speed TP. Summaries of affymetrix genechip probe level data. Nucleic Acids Res. 2003;31(4):e15.

31. Leek JT, Johnson WE, Parker HS, Jaffe AE, Storey JD. The sva package for removing batch effects and other unwanted variation in high-throughput experiments. Bioinformatics. 2012;28(6):882–3.

32. Troyanskaya O, Cantor M, Sherlock G, Brownet P, Hastie T, Tibshirani R, Botstein D, Altman RB. Missing value estimation methods for DNA microarrays. Bioinformatics. 2001;17(6):520–5.

33. Matthew ER, Belinda P, Di W, Yifang H, Charity WL, Wei S, Gordon KS. Limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43(7):e47.

34. Karin B, Amir KF, Matthew RL, Carol C, Anastasia S, Raymond L, et al. InnateDB: systems biology of innate immunity and beyond—recent updates and continuing curation. Nucleic Acids Res. 2013;41(Database issue):D1228-33.

**Tables**

Table 1

| Clinical characteristics                  | Values   | Cases |
|------------------------------------------|----------|-------|
| Disease severity                         | Mild     | 13    |
|                                          | Moderate | 59    |
|                                          | Severe   | 60    |
| Brodalumab therapeutic efficacy (%)      | 89.94 ± 21.05 | 32    |
| Ustekinumab therapeutic efficacy (%)     | 79.82 ± 17.66 | 26    |

**Figures**
**Figure 1**

Landscape of innate immune cell infiltration in psoriasis. a. Comparison of innate immune cells between psoriasis lesional skin and normal skin. b. Comparison of innate immune cells between psoriasis lesional skin and non-lesional skin. * P < 0.05, ** P < 0.01, *** P < 0.001.
Figure 2

The differences of innate immune cell infiltration among mild, moderate and severe psoriasis. The fraction of M0 macrophages or resting mast cells was significantly different. Black bar: median. * P < 0.05, ** P < 0.01.
Figure 3

Venn plot illustrating differentially expressed innate immune genes.
Figure 4

Correlation of core genes with clinical features and innate immune cells. a. Spearman correlation analysis between core genes and clinical characteristics, including disease severity, therapeutic efficacy of brodalumab and ustekinumab. b. Spearman correlation analysis of core genes and proportion of innate immune cells. * P < 0.05, ** P < 0.01, *** P < 0.001.
Figure 5

Pathways associated with core gene alteration predicted by GSEA. The alteration was the comparison between high-expression group and low-expression group. Pathways enriched in phenotype high were shown in red (right), and pathways enriched in phenotype low were shown in blue (left). All gene sets were significantly enriched at nominal p < 5% and False discovery rate < 25%. 